Research programme: sodium channel blockers - RaQualia Pharma
Alternative Names: RQ-00203066Latest Information Update: 28 Jul 2018
Price :
$50 *
At a glance
- Originator Pfizer
- Developer RaQualia Pharma
- Class Amides
- Mechanism of Action Nav1.3 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Inflammatory pain; Neuropathic pain
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Inflammatory-pain in Japan
- 28 Jul 2018 No recent reports of development identified for research development in Neuropathic-pain in Japan
- 27 Jul 2016 Early research and development is ongoing in Japan